Tirzepatide (60mg)

Tirzepatide (60mg)

Current price is: $349.99. Original price was: $530.00.

Compound Tirzepatide (60mg)
Category Metabolic Research
Purity ≥ 99% (HPLC & Mass Spec Verified)
Form Lyophilised Powder
Storage (Lyophilised) -20 °C — protect from light & moisture
Storage (Reconstituted) 2–8 °C — use within 8–12 weeks

⚠ For in-vitro research and laboratory use only. Not intended for human or veterinary use. By purchasing, you confirm you are a qualified researcher and will use this compound in accordance with all applicable laws and regulations.

Tirzepatide (60mg)

Current price is: $349.99. Original price was: $530.00.

Add to cart
Buy Now
SKU: PEP-021-60MG Category:

Dual GLP-1/GIP Agonist — Maximum-Capacity Research Vial

Tirzepatide (60mg) will be supplied in Australia by Daza Enhanced with fast domestic shipping to all states and territories.

The 60mg vial provides 3× the compound of the 20mg vial and 50% more than the 40mg — same purity, same batch-verified CoA, the lowest cost per milligram of any Tirzepatide format we offer, and the fewest reconstitution cycles across an extended research protocol.

Tirzepatide is a dual incretin agonist that activates both GLP-1 and GIP receptors. Where semaglutide (Ozempic/Wegovy) acts on GLP-1 alone, Tirzepatide’s dual activity is associated with stronger outcomes in clinical research: Phase 3 SURMOUNT trials reported mean body weight reductions of up to 22.5% over 72 weeks — one of the largest figures documented in weight-management research. Tirzepatide established the dual-agonist benchmark now used to evaluate newer tri-agonist compounds like Retatrutide.

Mechanism of research interest: GLP-1 activation modulates appetite and gastric emptying; GIP activation modulates insulin sensitivity and fat metabolism. The combined signal is studied for appetite reduction, glycaemic control, and preferential fat-mass reduction.

Key Research Areas

  • Fat Loss Research — Up to 22.5% body weight reduction over 72 weeks in Phase 3 trials
  • Appetite Regulation — Studied for reduced food intake via gastric emptying and central appetite signalling
  • Glycaemic Control — Studied for insulin sensitivity and HbA1c reduction in type 2 diabetes research
  • Body Composition — Studied for preferential fat-mass reduction over lean mass
  • Cardiometabolic Markers — Studied for blood pressure, cholesterol, and cardiovascular risk improvements
  • Hepatic Steatosis — Emerging research on fatty liver markers and NASH-related models

Supplied as lyophilized powder, verified by HPLC and mass spectrometry. 60mg per vial. Fast domestic shipping across Australia, with batch-specific CoA information available in our CoA Library.

⚠ For in-vitro research and laboratory use only. Not for human consumption.

Reviews

There are no reviews yet.

Be the first to review “Tirzepatide (60mg)”

Your email address will not be published. Required fields are marked *